Q1 Earnings Estimate for MNMD Issued By Leerink Partnrs

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Mind Medicine (MindMed) in a note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings of ($0.35) per share for the quarter. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Mind Medicine (MindMed)’s Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.47) EPS and FY2028 earnings at ($1.65) EPS.

Other equities analysts have also issued research reports about the company. Oppenheimer reissued an “outperform” rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a research note on Tuesday, December 17th. Chardan Capital began coverage on shares of Mind Medicine (MindMed) in a report on Friday, December 20th. They issued a “buy” rating and a $20.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Evercore ISI began coverage on Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They set an “outperform” rating and a $23.00 target price for the company. Finally, Robert W. Baird reduced their price objective on shares of Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, March 7th. Ten research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $25.11.

Mind Medicine (MindMed) Price Performance

Shares of MNMD stock opened at $5.60 on Wednesday. The firm’s 50 day moving average price is $6.70 and its two-hundred day moving average price is $6.90. The stock has a market cap of $422.06 million, a PE ratio of -2.48 and a beta of 2.54. Mind Medicine has a 52-week low of $4.70 and a 52-week high of $10.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.00 and a current ratio of 9.00.

Mind Medicine (MindMed) (NASDAQ:MNMD) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.08). During the same period in the previous year, the company posted ($0.59) EPS.

Institutional Investors Weigh In On Mind Medicine (MindMed)

Hedge funds have recently added to or reduced their stakes in the business. Corebridge Financial Inc. raised its position in shares of Mind Medicine (MindMed) by 4.1% during the fourth quarter. Corebridge Financial Inc. now owns 40,064 shares of the company’s stock worth $279,000 after purchasing an additional 1,569 shares during the period. Commonwealth Equity Services LLC boosted its stake in shares of Mind Medicine (MindMed) by 9.9% in the 4th quarter. Commonwealth Equity Services LLC now owns 21,492 shares of the company’s stock worth $150,000 after buying an additional 1,928 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Mind Medicine (MindMed) by 21.9% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 12,430 shares of the company’s stock worth $87,000 after purchasing an additional 2,230 shares during the period. Woodline Partners LP boosted its stake in Mind Medicine (MindMed) by 0.3% in the fourth quarter. Woodline Partners LP now owns 1,005,198 shares of the company’s stock valued at $6,996,000 after acquiring an additional 2,654 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Mind Medicine (MindMed) by 8.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 36,995 shares of the company’s stock worth $211,000 after acquiring an additional 2,797 shares during the period. 27.91% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Robert Barrow sold 21,208 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $142,941.92. Following the transaction, the chief executive officer now directly owns 856,556 shares of the company’s stock, valued at $5,773,187.44. The trade was a 2.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel Karlin sold 6,836 shares of Mind Medicine (MindMed) stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $46,074.64. Following the transaction, the insider now directly owns 446,177 shares of the company’s stock, valued at $3,007,232.98. This represents a 1.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,391 shares of company stock worth $204,835 in the last ninety days. 2.26% of the stock is owned by insiders.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.